MannaResearch Acquires Montreal Clinical Research Center, Offering Clients a Broader Geographic Reach and Access to More Patients

(Montreal, Quebec; July 11, 2013)  — MannaResearch, a group of industry-leading, independent clinical research centers, today announces the successful acquisition of Kells Medical Research Group, a Montreal-based clinical investigator site.

This acquisition represents the fourth Canadian research center MannaResearch has acquired in the past 15 months and its first in Montreal. With more than 15 years of clinical trial experience, Kells Medical Research Group is one of Montreal's largest primary care research centers and has a database of more than 200,000 patients. The acquisition brings the MannaResearch patient database to 350,000.

Dr. Graham Wood, MannaResearch's Chief Executive Officer, explains, "Within the industry, the Kells name is synonymous with quality and experience, making the company a perfect fit for MannaResearch. This acquisition represents a strategic addition to our rapidly expanding group of sites, helping us attain our goal of simplifying clinical research in Canada for pharmaceutical companies."

The acquisition supports MannaResearch's commitment to growth. Over the next few years MannaResearch plans to add additional research sites within Canada to provide its clients access to consistent, high-quality research centers across the nation.

About MannaResearch
MannaResearch is Canada's leading group of independent clinical investigator sites. Headquartered in Montreal, Canada, MannaResearch has been conducting clinical studies since 1996 and is now operating in Toronto, Vancouver, Montreal and Quebec City. MannaResearch consistently delivers quality data and simplifies the clinical research process by providing a trusted end-to-end solution that encompasses centralized feasibility while utilizing a set of standard operating procedures across all sites.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.